Dr. Steve Frese to speak at AAEP 2017! Learn more at Evolve Booth #2078
Evolve BioSystems is proud to participate in the American Association of Equine Practitioners annual meeting, taking place November 17-21, 2017 in San Antonio! Visit us at Booth #2078 to hear the latest on GlycoGuard, the first clinically proven probiotic for nursing foals.
Dr. Steve Frese, Evolve's Associate Director of Research and Development, will be presenting our latest clinical results in Monday's session titled, "Hot Topics in Equine Medicine - Gut, Bugs, Bleeders, and More," from 1:30-4:30pm in the Hemisfair Ballroom.
Come join Evolve to learn how our animal health product, GlycoGuard® supports a healthy gut microbiome in nursing foals. GlycoGuard, the first oral activated microbial gel for newborn foals, is a combination of two activated beneficial bacteria, B. infantis and L. plantarum, which selectively thrive on mare's milk. When provided to nursing foals immediately after birth, GlycoGuard works along with mare's milk to properly establish the intestinal microflora during these important first few weeks of life.
For more details on the event, click here
To learn more about GlycoGuard, visit us at: www.glycoguard.com
Evolve BioSystems Contact
Dr. Duane Maye
Director, Animal Health
About Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering. In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.